Your Entire Medicine Cabinet Might Be J&J

Open almost any American medicine cabinet and you will likely find products from what was, until recently, the consumer health division of Johnson & Johnson. Tylenol for pain relief. Band-Aid for cuts. Listerine for your mouth. Neutrogena in the skincare drawer. Benadryl in the allergy section.

These brands look independent. They compete for shelf space. They run separate marketing campaigns. But for most of the twentieth century, they all came from the same source. In 2023, Johnson & Johnson spun off its consumer health division into a separate publicly traded company called Kenvue. The brands did not change owners; they simply moved to a new corporate vehicle. For a related look at how corporate splits affect brand families, see our post on brand spin-offs when companies sell brands.

What Kenvue Is

Kenvue (NYSE: KVUE) launched as an independent public company through an IPO in May 2023, in what was one of the largest consumer health spinoffs in US corporate history. Johnson & Johnson distributed its remaining Kenvue shares to J&J shareholders in August 2023, completing the separation. As of early 2026, Kenvue operates as a fully independent company, though J&J retained no significant ongoing ownership stake.

Kenvue reported net sales of approximately $14.5 billion for FY2024, making it one of the largest standalone consumer health companies in the world. The company is headquartered in Summit, New Jersey, and employs approximately 22,000 people.

The portfolio spans three segments: Self Care, Skin Health and Beauty, and Essential Health.

The Self Care Cabinet

The Self Care segment covers over-the-counter medicines -- the products most likely to be in your medicine cabinet.

[Tylenol](/brands/tylenol) is the flagship. Johnson & Johnson acquired the brand in 1959, and it became one of the best-selling OTC pain relievers in the world. Tylenol's active ingredient is acetaminophen, and it commands approximately 35-40% of the US OTC pain reliever market by dollar sales. The brand also faced one of the most significant product safety crises in American corporate history: the 1982 Chicago Tylenol murders, in which seven people died after someone tampered with bottles on store shelves. Johnson & Johnson's recall and relaunch with tamper-resistant packaging became a crisis management case study still taught in business schools.

Motrin (ibuprofen) was acquired with the McNeil consumer division and competes in the OTC pain segment alongside Tylenol. Motrin IB is one of the leading ibuprofen brands in the US.

Benadryl (diphenhydramine) is among the best-known antihistamine brands globally. The Benadryl formulation for allergy relief has been on the market since the 1940s.

Zyrtec (cetirizine) is a newer-generation antihistamine that became available OTC in the US in 2008 after its prescription patent expired. Kenvue's Zyrtec competes with Claritin (Bayer) and Allegra (Chattem, now Sanofi) in the non-drowsy allergy category.

Pepcid (famotidine) covers the antacid and heartburn relief segment, competing with Prilosec (P&G) and Nexium (AstraZeneca/Bayer).

The Skincare and Beauty Cabinet

Kenvue's Skin Health and Beauty segment includes some of the most widely distributed skincare brands on the US market.

[Neutrogena](/brands/neutrogena) was acquired by Johnson & Johnson in 1994 for approximately $924 million. The brand holds a strong position in the dermatologist-recommended skincare category, with product lines covering cleansers, moisturizers, sunscreen, and acne treatment. Neutrogena generates estimated annual sales of over $1 billion.

Aveeno was acquired by J&J in 1999 and built around oat-based skincare formulations. The brand's positioning around natural and dermatologist-recommended ingredients gave it a premium position relative to mass-market competitors. Aveeno is one of Kenvue's top revenue generators.

Clean & Clear is a acne-focused skincare line primarily targeting teenagers, introduced by J&J in the 1990s.

RoC is a French skincare brand, part of the anti-aging segment, that J&J sold to a private equity group in 2019 but retained US marketing rights for a period. As of 2026, RoC operates as an independent brand under Gryphon Investors.

The Oral Care Cabinet

[Listerine](/brands/listerine) has been produced by Johnson & Johnson since 1881, when Joseph Lawrence formulated the antiseptic mouthwash in St. Louis. It is among the oldest consumer health brands still widely sold. Listerine holds dominant market share in the US mouthwash category, with approximately 40% of the antiseptic mouthwash segment by dollar sales.

[Band-Aid](/brands/band-aid) is Johnson & Johnson's most iconic consumer brand, introduced in 1920 by Earle Dickson, an employee whose wife frequently cut her fingers while cooking. The adhesive bandage became so synonymous with the product category that "Band-Aid" entered common language as a generic descriptor, a phenomenon the company actively protects through trademark enforcement.

The Consolidation Pattern

Johnson & Johnson assembled this portfolio over roughly eight decades through a combination of internal development and acquisitions. The strategy followed a deliberate pattern: acquire trusted, category-leading brands in adjacent OTC health segments, then leverage J&J's global distribution, marketing scale, and retailer relationships to grow them.

This is the same pattern visible across the consumer goods industry. As our post on why competing brands are owned by the same company explains, corporate ownership of seemingly rival products is rarely coincidental. Companies build portfolios to capture shelf space across multiple consumer segments, reduce dependence on any single brand, and spread operating costs.

The Kenvue separation does not change the underlying ownership concentration. The consumer health brands that millions of households use daily still form a single portfolio, just under a new parent entity.

What Changed After the Kenvue Spin-Off

For most consumers, nothing changed at the product level. The Tylenol you buy today is the same formulation it was in 2022. Neutrogena's packaging has not changed. Listerine is still made in the same facilities.

What changed was the corporate structure. Kenvue now operates as a standalone company with its own management team, its own board, and its own capital allocation priorities. J&J retained its pharmaceutical and medical device businesses under the Johnson & Johnson name. The theory behind the split was that the consumer health business had different growth dynamics, capital requirements, and competitive pressures than J&J's prescription pharmaceutical and MedTech operations, and would be better managed independently.

Kenvue's early years as a public company have been mixed. The company faced softening consumer demand in several categories and margin pressure from higher input costs through 2023 and 2024. Revenue trends stabilized in 2025, and the company refocused on premium positioning and digital consumer acquisition.

The Full Kenvue Brand Map

As of FY2025. Source: Kenvue Investor Relations

FAQ

Is Johnson & Johnson the same as Kenvue? No. As of August 2023, Kenvue is a fully independent, publicly traded company. Johnson & Johnson retained its pharmaceutical and MedTech businesses but distributed its Kenvue shares to J&J shareholders, completing a full separation. The consumer health brands -- Tylenol, Band-Aid, Neutrogena, Listerine -- are now owned by Kenvue (NYSE: KVUE), not Johnson & Johnson.

Does J&J still own Tylenol? Tylenol is owned by Kenvue, not Johnson & Johnson, as of 2023. Prior to the Kenvue IPO and separation, Tylenol was part of J&J's consumer segment. The brand transferred to Kenvue as part of the spinoff.

Is Neutrogena the same company as Aveeno? Both Neutrogena and Aveeno are owned by Kenvue. They operate as separate brands with distinct positioning -- Neutrogena leads in clinical skincare efficacy, while Aveeno is positioned around oat-based natural ingredients -- but they share Kenvue's manufacturing, distribution, and retail infrastructure.

Explore Related Brands

• Tylenol - Kenvue's flagship OTC pain reliever, US market leader since the 1970s
• Band-Aid - The original adhesive bandage brand, introduced 1920 by Johnson & Johnson
• Neutrogena - Dermatologist-recommended skincare, acquired by J&J in 1994
• Listerine - The original antiseptic mouthwash, in continuous production since 1881

Browse all healthcare and pharmaceutical brands

Sources

1. Kenvue IPO Prospectus, May 2023 -- https://investors.kenvue.com/ 2. Kenvue Annual Report FY2024 -- https://investors.kenvue.com/financial-information/annual-reports 3. Johnson & Johnson Separation Press Release, August 2023 -- https://www.jnj.com/media-center 4. FDA OTC Monograph Database -- https://www.accessdata.fda.gov/ 5. SEC EDGAR: Kenvue Inc. (KVUE) 10-K -- https://www.sec.gov/cgi-bin/browse-edgar

All brand ownership data verified through WhoBrands.com research methodology. Last updated: April 2026.